Julius has been named a New Innovator by the Director of the National Institutes of Health, Dr. Francis Collins. The goal of the NIH Director’s New Innovator Award Program is to support exceptionally creative new investigators who propose highly innovative projects that have the potential for unusually high impact.
The New Innovator Awards are supported by the NIH Common Fund, which was enacted into law by Congress through the 2006 NIH Reform Act, which supports trans-NIH programs with a particular emphasis on innovation and risk taking. The NIH Common Fund encourages collaboration and supports a series of exceptionally high impact, trans-NIH programs. Common Fund programs are designed to pursue major opportunities and gaps in biomedical research that no single NIH Institute could tackle alone, but that the agency as a whole can address to make the biggest impact possible on the progress of medical research. Julius is the fifth Cornell faculty member to receive this award since its inception in 2007.
As an NIH New Innovator, we will develop an ‘omics’ technology to elucidate how RNAs fold inside the cell. This technology development will provide a new tool which they will use in their overall mission to truly understand, engineer, and correct RNA function in biological systems and prevent disease.
A special thanks to David Loughrey and Helen Tan for getting some awesome preliminary data on our approach that was clearly well receieved!
For more information see:
- Cornell Chronicle:http://www.news.cornell.edu/stories/2013/09/lucks-seandel-are-nih-new-innovators
- NIH Press Release:http://www.nih.gov/news/health/sep2013/od-30.htm
- CBE Website: http://www.cheme.cornell.edu/news/index.cfm?news_id=64190
- SynBERC Website: http://synberc.org/content/synberc-affiliated-pis-named-nih-directors-new-innovators
- NIH New Innovator Award Program:https://commonfund.nih.gov/newinnovator/